Skip to main content

Table 1 Clinical characteristics of patients with GvHD

From: GVHD-derived plasma as a priming strategy of mesenchymal stem cells

GvHD classificationSampleAgeSexDiagnosisSCT sourceGvHD affected organ/scoreGvHD prophylaxis
AcuteGA114MAABMSkin ISIRO + MMF
GA210FALLBMSkin IIISIRO + MMF
GA344FAABMEyes I/mouth I
GA430FB-ALLBMMouth I/liver ISIRO
GA519MALLBMSkin/liverbPrednisone
GA621MAA/PNH+BMSkin IV/liver/GIbPrednisone + MMF
GA712MB-ALLBMSkin IIICSA
ChronicGC126MBAL/MRD+BMMild
GC236MCMLBMMild
GC352FAMLPBSCCSA + prednisone
GC441FBAL/MRD+PBSCModerateCSA
GC550FCMLBMCSA
GC643MCMLPBSCModerateCSA + prednisone
GC712MALLBMMild
GC824FAMLPBSCMild
GC970MAMLBMMildCSA
GC1069MAMLBMSevereCSA
GC11a61MMyelofibrosisPBSCModerateCSA + MMF
GC1243MCMLPBSCSevere
  1. M male, F female, AA aplastic anemia, ALL acute lymphoblastic leukemia, AML acute myeloblastic leukemia, BAL biphenotypic acute leukemia, BM bone marrow, CML chronic myeloid leukemia, CSA cyclosporine, MMF mycophenolate mofetil, MRD minimal residual disease, PBSC peripheral blood stem cells, PNH paroxymal nocturnal hemoglobinuria, SCT stem cell transplantation, SIRO sirolimus
  2. aOverlap syndrome
  3. bNon-classified